Take Homes in Renal Cell Carcinoma

MADRID — MEDI5752, a novel bispecific antibody binding to CTLA-4 and PD-1, showed potential as a first-line treatment in patients with advanced clear cell renal cell carcinoma, according to data presented at ESMO Congress.

MADRID — Moshe Ornstein, MD, discussed the results of LITESPARK-005 presented at ESMO Congress in a video interview with Healio.

MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal cell carcinoma presented at ESMO Congress.

MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.

MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.

MADRID — Treatment with toripalimab plus axitinib resulted in significantly longer PFS than treatment with sunitinib in patients with previously untreated advanced kidney cancer, according to a presentation from ESMO Congress.

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.

MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.

MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.

In this video, Farshid Sadeghi, MD, discussed data for a study examining cabozantinib-resistant kidney cancer at American Urological Association Annual Meeting.